Trinity Biotech plc
TRIB · NASDAQ
3/31/2025 | 12/31/2024 | 9/30/2024 | 6/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.02 | -0.01 | 0.09 | -0.04 |
| FCF Yield | -5.79% | 0.99% | -11.07% | -4.10% |
| EV / EBITDA | -26.68 | -16.46 | -133.10 | -49.28 |
| Quality | ||||
| ROIC | -6.60% | -16.20% | -3.54% | -5.60% |
| Gross Margin | 20.67% | 30.76% | 35.03% | 36.19% |
| Cash Conversion Ratio | 0.34 | -0.20 | 0.76 | 0.16 |
| Growth | ||||
| Revenue 3-Year CAGR | -8.41% | -6.28% | -8.14% | -9.36% |
| Free Cash Flow Growth | -590.77% | 109.73% | -48.18% | 32.12% |
| Safety | ||||
| Net Debt / EBITDA | -17.77 | -9.96 | -81.72 | -22.57 |
| Interest Coverage | -2.05 | -2.69 | -0.83 | -1.43 |
| Efficiency | ||||
| Inventory Turnover | 0.30 | 0.57 | 0.45 | 0.44 |
| Cash Conversion Cycle | 57.70 | 185.68 | 95.28 | 99.56 |